Search company, investor...


Founded Year



Series B | Alive

Total Raised


Last Raised

$30M | 1 yr ago


ABMTX is a drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers including GBM, as well as brain metastasis from melanoma, lung cancer, and breast cancer.

Headquarters Location

780 Cailun Road Suite 809

Shanghai, Shanghai, 201203,


86 21 50273126

Missing: ABMTX's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ABMTX's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ABMTX

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ABMTX is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest ABMTX News

ABM Therapeutics doses first patient in Phase I solid tumours trial

May 5, 2023

ABM-168 has good water solubility, high cell permeability and brain penetration properties. Anti-cancer properties, specifically in intracranial animal models, have also been demonstrated in favour of ABM-168. ABM Therapeutics has dosed the first patient in the US in a Phase I clinical trial of ABM-168 , a novel small molecule mitogen-activated protein kinase (MEK) inhibitor, for solid tumours. Designed to evaluate the tolerability, pharmacokinetics and safety of ABM-168 monotherapy, the first-in-human open-label, multicentre, cohort expansion and dose escalation study will be carried out in adult patients with advanced/metastatic solid tumours. Recommended Reports Anti-cancer properties, specifically in intracranial animal models, have also been demonstrated in favour of ABM-168. ABM Therapeutics CMO Dr Zane Yang said: “We are very pleased to reach our study’s first patient dosed milestone at NEXT Oncology – Dallas, one of the clinical trial centres for this novel MEK inhibitor and collaborate with all study sites and investigators.” In October last year, the US FDA cleared investigational new drug (IND) application for ABM-168 to proceed with the first-in-human trial. ABM Therapeutics founder and CEO Dr Chen Chen said: “Selective MEK inhibitors have the ability to inhibit tumour growth and induce cell death in RAF- and RAS-mutant cell lines. A MEK inhibitor in combination with a BRAF inhibitor has been demonstrated to be more effective and less toxic than a single BRAF inhibitor, which has become the standard of care for patients with BRAF-mutated melanoma. “The combination of a MEK inhibitor with other anti-cancer drugs such as KRAS inhibitors and PD-1/PD-L1 antibodies is also explored. “We look forward to the early clinical data which will help us to figure out the most effective combination for treating cancers, particularly those with high brain metastasis rates.” Share this article

ABMTX Frequently Asked Questions (FAQ)

  • When was ABMTX founded?

    ABMTX was founded in 2015.

  • Where is ABMTX's headquarters?

    ABMTX's headquarters is located at 780 Cailun Road, Shanghai.

  • What is ABMTX's latest funding round?

    ABMTX's latest funding round is Series B.

  • How much did ABMTX raise?

    ABMTX raised a total of $51.1M.

  • Who are the investors of ABMTX?

    Investors of ABMTX include LongDAC, Delta Capital, Photon Fund, HighLight Capital, Hermed Capital and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.